Liver Toxicities Typically Induced by First-Generation Adenoviral Vectors Can Be Reduced by Use of E1, E2b-Deleted Adenoviral Vectors

Human Gene Therapy

Volumn 14, Issue 18, 2003, Pages 1715-1726

  Everett, R S ^a   Hodges, B L ^a   Ding, E Y ^a   Xu, F ^a   Serra, D ^a   Amalfitano, A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE DELETION; GENE TRANSFER; IMMUNE RESPONSE; IMMUNOCOMPETENCE; LIVER TOXICITY; MARKER GENE; MOUSE; MOUSE STRAIN; NONHUMAN; TRANSGENE;

ADENOVIRIDAE; ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 0346256668     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303403322611737     Document Type: Article

References (28)

1. AMALFITANO, A., and PARKS, R.J. (2002). Separating fact from fiction: Assessing the potential of modified adenovirus vectors for use in human gene therapy [review]. Curr. Genet. Ther. 2, 111-133.
2. AMALFITANO, A., HAUSER, M.A., HU, H., SERRA, D., BEGY, C.R., and CHAMBERLAIN, J.S. (1998). Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J. Virol. 72, 926-933.
3. BARR, D., TUBB, J., FERGUSON, D., SCARIA, A., LIEBER, A., WILSON, C., PERKINS, J., and KAY, M.A. (1995). Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther. 2, 151-155.
4. BROUGH, D.E., LIZONOVA, A., HSU, C., KULESA, V.A., and KOVESDI, I. (1996). A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J. Virol. 70, 6497-6501.
5. CHRIST, M., LOUIS, B., STOECKEL, F., DIETERLE, A., GRAVE, L., DREYER, D., KINTZ, J., ALI HADJI, D., LUSKY, M., and MEHTALI, M. (2000). Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products. Hum. Gene Ther. 11, 415-427.
6. DEDIEU, J.F., VIGNE, E., TORRENT, C., JULLIEN, C., MAHFOUZ, I., CAILLAUD, J.M., AUBAILLY, N., ORSINI, C., GUILLAUME, J.M., OPOLON, P., DELAERE, P., PERRICAUDET, M., and YEH, P. (1997). Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J. Virol. 71, 4626-4637.
7. -] adenovirus mediated transfer of the human acid-α-glucosidase gene into GSD-II knockout mice. Hum. Gene Ther. 12, 955-965.
8. DING, E., HU, H., HODGES, B.L., MIGONE, F., SERRA, D., XU, F., CHEN, Y.T., and AMALFITANO, A. (2002). Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction. Mol. Ther. 5, 436-446.
9. GAO, G.P., YANG, Y.P., and WILSON, J.M. (1996). Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J. Virol. 70, 8934-8943.
10. GASCA, S., HILL, D.P., KLINGENSMITH, J., and ROSSANT, J. (1995). Characterization of a gene trap insertion into a novel gene, cordon-bleu, expressed in axial structures of the gastrulating mouse embryo. Dev. Genet. 17, 141-154.
11. -] adenovirus vector expressing human apoE. Hum. Mol. Genet. 11, 43-58.
12. -] adenovirus vector persists despite deletion of the preterminal protein. J. Gene Med. 2, 250-259.
13. HODGES, B.L., EVANS, H.K., EVERETT, R.S., DING, E.Y., SERRA, D., and AMALFITANO, A. (2001). Adenovirus vectors with the 100K gene deleted and their potential for multiple gene therapy applications. J. Virol. 75, 5913-5920.
14. -] adenovirus vector despite transduction of a neoantigen into immune-competent mice. Hum. Gene Ther. 10, 355-364.
15. KIM, I.H., JOZKOWICZ, A., PIEDRA, P.A., OKA, K., and CHAN, L. (2001). Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc. Natl. Acad. Sci. U.S.A. 98, 13282-13287.
16. LOCHMULLER, H., JANI, A., HUARD, J., PRESCOTT, S., SIMONEAU, M., MASSIE, B., KARPATI, G., and ACSADI, G. (1994). Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (ΔE1 + ΔE3) during multiple passages in 293 cells. Hum. Gene Ther. 5, 1485-1491.
17. LUSKY, M., CHRIST, M., RITTNER, K., DIETERLE, A., DREYER, D., MOUROT, B., SCHULTZ, H., STOECKEL, F., PAVIRANI, A., and MEHTALI, M. (1998). In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2a, or E1/E4 deleted. J. Virol. 72, 2022-2032.
18. 1-antitrypsin with negligible toxicity. Hum. Gene Ther. 9, 2709-2716.
19. MORRAL, N., O'NEAL, W., RICE, K., LELAND, M., KAPLAN, J., PIEDRA, P.A., ZHOU, H., PARKS, R.J., VELJI, R., AGUILAR-CORDOVA, E., WADSWORTH, S., GRAHAM, F.L., KOCHANEK, S., CAREY, K.D., and BEAUDET, A.L. (1999). Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc. Natl. Acad. Sci. U.S.A. 96, 12816-12821.
20. 1-antitrypsin after systemic delivery. Hum. Gene Ther. 9, 1587-1598.
21. PASTORE, L., MORRAL, N., ZHOU, H., GARCIA, R., PARKS, R.J., KOCHANEK, S., GRAHAM, F.L., LEE, B., and BEAUDET, A.L. (1999). Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum. Gene Ther. 10, 1773-1781.
22. SCHIEDNER, G., MORRAL, N., PARKS, R.J., WU, Y., KOOPMANS, S.C., LANGSTON, C., GRAHAM, F.L., BEAUDET, A.L., and KOCHANEK, S. (1998). Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat. Genet. 18, 180-183.
23. SCHOWALTER, D.B., HIMEDA, C.L., WINTHER, B.L., WILSON, C.B., and KAY, M.A. (1999). Implication of interfering antibody formation and apoptosis as two different mechanisms leading to variable duration of adenovirus-mediated transgene expression in immune-competent mice. J. Virol. 73, 4755-4766.
24. TRIPATHY, S.K., SVENSSON, E.C., BLACK, H.B., GOLDWASSER, E., MARGALITH, M., HOBART, P.M., and LEIDEN, J.M. (1996). Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. Proc. Natl. Acad. Sci. U.S.A. 93, 10876-10880.
25. WANG, Q., GREENBURG, G., BUNCH, D., FARSON, D., and FINER, M.H. (1997). Persistent transgene expression in mouse liver following in vivo gene transfer with a ΔE1/ΔE4 adenovirus vector. Gene Ther. 4, 393-400.
26. YANG, Y., NUNES, F.A., BERENCSI, K., FURTH, E.E., GONCZOL, E., and WILSON, J.M. (1991). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 91, 4407-4411.
27. YANG, Y., SU, Q., and WILSON, J.M. (1996). Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J. Virol. 70, 7209-7212.
28. ZHOU, H.S., O'NEAL, W., MORRAL, N., and BEAUDET, A.L. (1996). Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted. J. Virol. 70, 7030-7038.